Empirische Therapie bei febriler Neutropenie: Der richtige Zeitpunkt für eine antimykotische Therapie

Melden Sie sich bitte hier kostenlos und unverbindlich an, um den Inhalt vollständig einzusehen und weitere Services von www.medmedia.at zu nutzen.

Zur Anmeldung

AutorIn: Univ.-Prof. Dr. Romuald Bellmann

Arbeitsgruppe Klinische Pharmakokinetik, Gemeinsame Einrichtung Internistische Intensiv- und Notfallmedizin, Universitätsklinik für Innere Medizin I, Medizinische Universität Innsbruck

1 Freifeld AG et al., Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011; 52:e56–93
2 Walsh TJ et al., Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346:225–234
3 Kern WV, Risk assessment and treatment of low-risk patients with febrile neutropenia. Clin Infect Dis 2006; 42:533–540
4 Klastersky J et al., The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18:3038–3051
5 Pizzo PA et al., Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982; 72:101–111
6 Empiric antifungal therapy in febrile granulocytopenic patients. EORTC International Antimicrobial Therapy Cooperative Group. Am J Med 1989; 86:668–672
7 Maertens J et al., European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3–2009 update. Bone Marrow Transplant 2011; 46:709–718
8 Mousset S et al., Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2014; 93:13–32
9 Bellmann R, Pharmacodynamics and pharmacokinetics of antifungals for treatment of invasive aspergillosis. Curr Pharm Des 2013; 19:3629–3647
10 White MH et al., Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998; 27:296–302
11 Walsh TJ et al., 1999. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340:764–771
12 Boogaerts M et al., Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 2001; 135:412–422
13 Walsh TJ et al., Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351:1391–1402.
14 European Medicines Agency, Mycamine 2011, posting date. EPAR-Product Information. [Online.]
15 Wingard JR et al., A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 2000; 31:1155–1163
16 Girmenia C et al., A hematology consensus agreement on antifungal strategies for neutropenic patients with hematological malignancies and stem cell transplant recipients. Gruppo Italiano Malattie Ematologiche dell‘Adulto, Gruppo Italiano Trapianto di Midollo Osseo, Associazione Italiana Ematologia ed Oncologia Pediatrica, Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer and Sorveglianza Epidemiologica delle Infezioni Fungine nelle Emopatie Maligne. Hematol Oncol 2013; 31:117–126
17 Goldstone AH, O’Driscoll A, Early AmBisome in febrile neutropenia in patients with haematological disorders. Bone Marrow Transplant 1994; 14 Suppl 5:S15–17
18 Fukuda M et al., Empiric therapy with fluconazole in granulocytopenic patients with carcinoma or leukemia. Jpn J Antibiot 1994; 47:1065–1070
19 Wingard JR et al., Prevention of fungal sepsis in patients with prolonged neutropenia: a randomized, double-blind, placebo-controlled trial of intravenous miconazole. Am J Med 1987; 83:1103–1110
20 Goldberg E et al., Empirical antifungal therapy for patients with neutropenia and persistent fever: Systematic review and meta-analysis. Eur J Cancer 2008; 44:2192–2203
21 Maertens J et al., Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005; 41:1242–1250
22 Aguilar-Guisado M et al., Universal antifungal therapy is not needed in persistent febrile ne
utropenia: a tailored diagnostic and therapeutic approach. Haematologica 2012; 97:464–471
23 Cordonnier C et al., Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 2009; 48:1042–1051
24 Hebart H et al., A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT. Bone Marrow Transplant 2009; 43:553–561.
25 Schneider T et al., Pre-emptive diagnosis and treatment of fungal infections – evaluation of a single-centre policy. Clin Microbiol Infect 2012; 18:189–194
26 Tan BH et al., Galactomannan-guided preemptive vs. empirical antifungals in the persistently febrile neutropenic patient: a prospective randomized study. Int J Infect Dis 2011; 15:e350–356

Klinik 05|2014

Herausgeber: MedMedia Verlag und Mediaservice GmbH
Publikationsdatum: 2014-11-05